A review of ceramide analogs as potential anticancer agents

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Huwiler A, Zangemeister-Wittke U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit. Rev. Oncol. Hematol.63(2),150–159 (2007).
  MedlineGoogle Scholar
• 2  Takabe K, Paugh SW, Milstien S, Spiegel S. ‘Inside-out’ signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev.60(2),181–195 (2008).
  Medline CASGoogle Scholar
• 3  Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta1485(2–3),63–99 (2000).
  Medline CASGoogle Scholar
• 4  Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer4(8),604–616 (2004).
  Medline CASGoogle Scholar
• 5  Zhou H, Summers SA, Birnbaum MJ, Pittman RN. Inhibition of AKT kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem.273(26),16568–16575 (1998).
  Medline CASGoogle Scholar
• 6  Bourbon NA, Sandirasegarane L, Kester M. Ceramide-induced inhibition of AKT is mediated through protein kinase Czeta: implications for growth arrest. J. Biol. Chem.277(5),3286–3292 (2002).
  Medline CASGoogle Scholar
• 7  Wang G, Silva J, Krishnamurthy K, Tran E, Condie BG, Bieberich E. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem.280(28),26415–26424 (2005).
  Medline CASGoogle Scholar
• 8  Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2’s antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood113(2),422–428 (2009).
  Medline CASGoogle Scholar
• 9  Heinrich M, Neumeyer J, Jakob M et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ.11(5),550–563 (2004).
  Medline CASGoogle Scholar
• 10  Lee H, Rotolo JA, Mesicek J et al. Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation. PLoS ONE6(6),e19783 (2011).
  Medline CASGoogle Scholar
• 11  Von Haefen C, Wieder T, Gillissen B et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene21(25),4009–4019 (2002).
  Medline CASGoogle Scholar
• 12  Beckham TH, Lu P, Jones EE et al. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J. Pharmacol. Exp. Ther.344(1),167–178 (2013).▪ Positively charged ceramide analog LCL124.
  Medline CASGoogle Scholar
• 13  Dahm F, Bielawska A, Nocito A et al. Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br. J. Cancer98(1),98–105 (2008).
  Medline CASGoogle Scholar
• 14  Chalfant CE, Szulc Z, Roddy P, Bielawska A, Hannun YA. The structural requirements for ceramide activation of serine-threonine protein phosphatases. J. Lipid Res.45(3),496–506 (2004).
  Medline CASGoogle Scholar
• 15  Bielawska A, Greenberg MS, Perry D et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J. Biol. Chem.271(21),12646–12654 (1996).
  Medline CASGoogle Scholar
• 16  Azuma H, Ijichi S, Kataoka M et al. Short-chain 3-ketoceramides, strong apoptosis inducers against human leukemia HL-60 cells. Bioorg. Med. Chem.15(8),2860–2867 (2007).
  Medline CASGoogle Scholar
• 17  Bernardo K, Hurwitz R, Zenk T et al. Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem.270(19),11098–11102 (1995).
  Medline CASGoogle Scholar
• 18  El Bawab S, Roddy P, Qian T, Bielawska A, Lemasters JJ, Hannun YA. Molecular cloning and characterization of a human mitochondrial ceramidase. J. Biol. Chem.275(28),21508–21513 (2000).
  Medline CASGoogle Scholar
• 19  Tani M, Okino N, Mitsutake S, Tanigawa T, Izu H, Ito M. Purification and characterization of a neutral ceramidase from mouse liver. A single protein catalyzes the reversible reaction in which ceramide is both hydrolyzed and synthesized. J. Biol. Chem.275(5),3462–3468 (2000).
  Medline CASGoogle Scholar
• 20  Okino N, Tani M, Imayama S, Ito M. Purification and characterization of a novel ceramidase from Pseudomonas aeruginosa.?. J. Biol. Chem.273(23),14368–14373 (1998).
  Medline CASGoogle Scholar
• 21  Raisova M, Goltz G, Bektas M et al. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett.516(1–3),47–52 (2002).
  Medline CASGoogle Scholar
• 22  Samsel L, Zaidel G, Drumgoole HM et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate58(4),382–393 (2004).
  Medline CASGoogle Scholar
• 23  Granot T, Milhas D, Carpentier S et al. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia20(3),392–399 (2006).
  Medline CASGoogle Scholar
• 24  Ichikawa S, Sakiyama H, Suzuki G, Hidari KI, Hirabayashi Y. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc. Natl Acad. Sci. USA93(10),4638–4643 (1996).
  Medline CASGoogle Scholar
• 25  Song M, Zang W, Zhang B, Cao J, Yang G. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells. J. Exp. Clin. Cancer Res. CR31,23 (2012).
  MedlineGoogle Scholar
• 26  Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem.274(2),1140–1146 (1999).
  Medline CASGoogle Scholar
• 27  Liu YY, Yu JY, Yin D et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J.22(7),2541–2551 (2008).
  Medline CASGoogle Scholar
• 28  Liu YY, Gupta V, Patwardhan GA et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer9,145 (2010).
  MedlineGoogle Scholar
• 29  Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta1771(12),1407–1417 (2007).
  Medline CASGoogle Scholar
• 30  Gouazé V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res.65(9),3861–3867 (2005).
  Medline CASGoogle Scholar
• 31  Sietsma H, Veldman RJ, Kolk D et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res.6(3),942–948 (2000).
  Medline CASGoogle Scholar
• 32  Dijkhuis AJ, Klappe K, Jacobs S et al. PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol. Cancer Ther.5(3),593–601 (2006).
  Medline CASGoogle Scholar
• 33  Granado MH, Gangoiti P, Ouro A, Arana L, Gomez-Munoz A. Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. Biochim. Biophys. Acta1791(4),263–272 (2009).
  Medline CASGoogle Scholar
• 34  Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J. Lipid Res.45(1),99–105 (2004).
  Medline CASGoogle Scholar
• 35  Gangoiti P, Granado MH, Wang SW, Kong JY, Steinbrecher UP, Gomez-Munoz A. Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. Cell. Signal.20(4),726–736 (2008).
  Medline CASGoogle Scholar
• 36  Gangoiti P, Bernacchioni C, Donati C et al. Ceramide 1-phosphate stimulates proliferation of C2C12 myoblasts. Biochimie94(3),597–607 (2012).
  Medline CASGoogle Scholar
• 37  Sauer B, Gonska H, Manggau M et al. Sphingosine 1-phosphate is involved in cytoprotective actions of calcitriol in human fibroblasts and enhances the intracellular Bcl-2/Bax rheostat. Pharmazie60(4),298–304 (2005).
  Medline CASGoogle Scholar
• 38  Avery K, Avery S, Shepherd J, Heath PR, Moore H. Sphingosine-1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells. Stem Cells Dev.17(6),1195–1205 (2008).
  Medline CASGoogle Scholar
• 39  Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl Acad. Sci. USA95(9),4997–5002 (1998).
  MedlineGoogle Scholar
• 40  Bektas M, Jolly PS, Müller C, Eberle J, Spiegel S, Geilen CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene24(1),178–187 (2005).
  Medline CASGoogle Scholar
• 41  Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer10(7),489–503 (2010).
  Medline CASGoogle Scholar
• 42  Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl Acad. Sci. USA103(44),16394–16399 (2006).
  Medline CASGoogle Scholar
• 43  Calise S, Blescia S, Cencetti F, Bernacchioni C, Donati C, Bruni P. Sphingosine 1-phosphate stimulates proliferation and migration of satellite cells: role of S1P receptors. Biochim. Biophys. Acta1823(2),439–450 (2012).
  Medline CASGoogle Scholar
• 44  Wang F, Van Brocklyn JR, Hobson JP et al. Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis. J. Biol. Chem.274(50),35343–35350 (1999).
  Medline CASGoogle Scholar
• 45  Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol. Cell. Biol.23(5),1534–1545 (2003).
  Medline CASGoogle Scholar
• 46  Hsu A, Zhang W, Lee JF et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int. J. Oncol.40(5),1619–1626 (2012).
  Medline CASGoogle Scholar
• 47  Kim ES, Kim JS, Kim SG, Hwang S, Lee CH, Moon A. Sphingosine 1-phosphate regulates matrix metalloproteinase-9 expression and breast cell invasion through S1P3-Gαq coupling. J. Cell. Sci.124(Pt 13),2220–2230 (2011).
  Medline CASGoogle Scholar
• 48  English D, Welch Z, Kovala AT et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J.14(14),2255–2265 (2000).
  Medline CASGoogle Scholar
• 49  Bieberich E, Hu B, Silva J et al. Synthesis and characterization of novel ceramide analogs for induction of apoptosis in human cancer cells. Cancer Lett.181(1),55–64 (2002).
  Medline CASGoogle Scholar
• 50  Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br. J. Cancer81(3),423–430 (1999).
  Medline CASGoogle Scholar
• 51  Wang JD, Takahara S, Nonomura N et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate40(1),50–55 (1999).
  Medline CASGoogle Scholar
• 52  Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J. Pharmacol. Exp. Ther.307(2),468–475 (2003).
  Medline CASGoogle Scholar
• 53  Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res.11(9),3465–3474 (2005).
  Medline CASGoogle Scholar
• 54  Zolnik BS, Stern ST, Kaiser JM et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo.?. Drug Metab. Dispos.36(8),1709–1715 (2008).
  Medline CASGoogle Scholar
• 55  Morad SA, Levin JC, Shanmugavelandy SS et al. Ceramide – antiestrogen nanoliposomal combinations – novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol. Cancer Ther.11(11),2352–2361 (2012).
  Medline CASGoogle Scholar
• 56  Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J. Biol. Chem.268(35),26226–26232 (1993).▪▪ Stereospecific activity of ceramide analogs.
  Medline CASGoogle Scholar
• 57  Bielawska A, Linardic CM, Hannun YA. Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. J. Biol. Chem.267(26),18493–18497 (1992).
  Medline CASGoogle Scholar
• 58  Karasavvas N, Erukulla RK, Bittman R, Lockshin R, Zakeri Z. Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis. Eur. J. Biochem.236(2),729–737 (1996).
  Medline CASGoogle Scholar
• 59  Szulc ZM, Bai A, Bielawski J et al. Synthesis, NMR characterization and divergent biological actions of 2´-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells. Bioorg. Med. Chem.18(21),7565–7579 (2010).
  Medline CASGoogle Scholar
• 60  Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell. Signal.23(10),1590–1595 (2011).
  Medline CASGoogle Scholar
• 61  Buehrer BM, Bell RM. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J. Biol. Chem.267(5),3154–3159 (1992).
  Medline CASGoogle Scholar
• 62  Usta J, El Bawab S, Roddy P et al. Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidase. Biochemistry40(32),9657–9668 (2001).
  Medline CASGoogle Scholar
• 63  Vunnam RR, Radin NS. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids26(3),265–278 (1980).▪▪ Discovery of RV-583 as a competitive glucosylceramide synthase inhibitor.
  Medline CASGoogle Scholar
• 64  Selzner M, Bielawska A, Morse MA et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res.61(3),1233–1240 (2001).
  Medline CASGoogle Scholar
• 65  Dagan A, Wang C, Fibach E, Gatt S. Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim. Biophys. Acta1633(3),161–169 (2003).
  Medline CASGoogle Scholar
• 66  Holman DH, Turner LS, El-Zawahry A et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol.61(2),231–242 (2008).
  Medline CASGoogle Scholar
• 67  Bhabak KP, Kleuser B, Huwiler A, Arenz C. Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues. Bioorg. Med. Chem.21(4),874–882 (2012).
  MedlineGoogle Scholar
• 68  Bai A, Szulc ZM, Bielawski J et al. Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg. Med. Chem.17(5),1840–1848 (2009).
  Medline CASGoogle Scholar
• 69  Bhabak KP, Arenz C. Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases. Bioorg. Med. Chem.20(20),6162–6170 (2012).
  Medline CASGoogle Scholar
• 70  Abe A, Inokuchi J, Jimbo M et al. Improved inhibitors of glucosylceramide synthase. J. Biochem.111(2),191–196 (1992).
  Medline CASGoogle Scholar
• 71  Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J. Lipid Res.28(5),565–571 (1987).
  Medline CASGoogle Scholar
• 72  Uemura K, Sugiyama E, Tamai C, Hara A, Taketomi T, Radin NS. Effect of an inhibitor of glucosylceramide synthesis on cultured rabbit skin fibroblasts. J. Biochem.108(4),525–530 (1990).
  Medline CASGoogle Scholar
• 73  Abe A, Radin NS, Shayman JA et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res.36(3),611–621 (1995).
  Medline CASGoogle Scholar
• 74  Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl Cancer Inst.92(23),1897–1909 (2000).
  Medline CASGoogle Scholar
• 75  Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem.274(21),14662–14669 (1999).
  Medline CASGoogle Scholar
• 76  Hillaert U, Boldin-Adamsky S, Rozenski J, Busson R, Futerman AH, van Calenbergh S. Synthesis and biological evaluation of novel PDMP analogues. Bioorg. Med. Chem.14(15),5273–5284 (2006).
  Medline CASGoogle Scholar
• 77  Larsen SD, Wilson MW, Abe A et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J. Lipid Res.53(2),282–291 (2012).
  Medline CASGoogle Scholar
• 78  Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y. N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry35(2),626–633 (1996).
  Medline CASGoogle Scholar
• 79  Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem.273(37),23722–23728 (1998).
  Medline CASGoogle Scholar
• 80  Liu H, Sugiura M, Nava VE et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem.275(26),19513–19520 (2000).
  Medline CASGoogle Scholar
• 81  Shirahama T, Sweeney EA, Sakakura C et al.In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3–1 and its multidrug-resistant cells. Clin. Cancer Res.3(2),257–264 (1997).
  Medline CASGoogle Scholar
• 82  Sweeney EA, Sakakura C, Shirahama T et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer66(3),358–366 (1996).
  Medline CASGoogle Scholar
• 83  Igarashi Y, Hakomori S, Toyokuni T et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry28(17),6796–6800 (1989).
  Medline CASGoogle Scholar
• 84  Sugiura M, Kono K, Liu H et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J. Biol. Chem.277(26),23294–23300 (2002).
  Medline CASGoogle Scholar
• 85  Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol.169(6),2372–2377 (2003).
  Medline CASGoogle Scholar
• 86  Ubai T, Azuma H, Kotake Y et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res.27(1A),75–88 (2007).
  Medline CASGoogle Scholar
• 87  Shen Y, Cai M, Xia W et al. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett.254(2),288–297 (2007).
  Medline CASGoogle Scholar
• 88  Nagaoka Y, Otsuki K, Fujita T, Uesato S. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol. Pharm. Bull.31(6),1177–1181 (2008).
  Medline CASGoogle Scholar
• 89  Estrada-Bernal A, Palanichamy K, Ray Chaudhury A, Van Brocklyn JR. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol.14(4),405–415 (2012).
  Medline CASGoogle Scholar
• 90  Azuma H, Takahara S, Ichimaru N et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res.62(5),1410–1419 (2002).
  Medline CASGoogle Scholar
• 91  Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther.4(9),1430–1438 (2005).
  Medline CASGoogle Scholar
• 92  Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced AKT dephosphorylation in leukemia cells. Br. J. Pharmacol.138(7),1303–1312 (2003).
  Medline CASGoogle Scholar
• 93  Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J. Biochem. Mol. Toxicol.21(5),273–279 (2007).
  Medline CASGoogle Scholar
• 94  Kharel Y, Lee S, Snyder AH et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem.280(44),36865–36872 (2005).
  Medline CASGoogle Scholar
• 95  Zemann B, Kinzel B, Müller M et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood107(4),1454–1458 (2006).
  Medline CASGoogle Scholar
• 96  Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem.277(24),21453–21457 (2002).
  Medline CASGoogle Scholar
• 97  Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J.18(3),551–553 (2004).
  Medline CASGoogle Scholar
• 98  Hamada M, Nakamura M, Kiuchi M et al. Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate. J. Med. Chem.53(8),3154–3168 (2010).
  Medline CASGoogle Scholar
• 99  Watson DG, Tonelli F, Al Osaimi M et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell. Signal.25(4),1011–1017 (2013).
  Medline CASGoogle Scholar
• 100  Shimizu H, Takahashi M, Kaneko T et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation111(2),222–229 (2005).
  Medline CASGoogle Scholar
• 101  Fujishiro J, Kudou S, Iwai S et al. Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation82(6),804–812 (2006).
  Medline CASGoogle Scholar
• 102  Bieberich E, Kawaguchi T, Yu RK. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J. Biol. Chem.275(1),177–181 (2000).
  Medline CASGoogle Scholar
• 103  Loveridge C, Tonelli F, Leclercq T et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem.285(50),38841–38852 (2010).
  Medline CASGoogle Scholar
• 104  Kono K, Tanaka M, Mizuno T, Kodama K, Ogita T, Kohama T. B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination. J. Antibiot. (Tokyo)53(8),753–758 (2000).
  Medline CASGoogle Scholar
• 105  Struckhoff AP, Bittman R, Burow ME et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther.309(2),523–532 (2004).▪ Introducing conjugated system into sphingosine backbone increasing apoptotic activity.
  Medline CASGoogle Scholar
• 106  De Jonghe S, Van Overmeire I, Gunst J et al. Synthesis and apoptogenic activity of fluorinated ceramide and dihydroceramide analogues. Bioorg. Med. Chem. Lett.9(21),3159–3164 (1999).
  Medline CASGoogle Scholar
• 107  Shikata K, Niiro H, Azuma H, Ogino K, Tachibana T. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg. Med. Chem.11(13),2723–2728 (2003).
  Medline CASGoogle Scholar
• 108  Shikata K, Niiro H, Azuma H, Tachibana T, Ogino K. Synthesis of non-natural C2-homo-ceramide and its apoptotic activity against HL-60 cells. Bioorg. Med. Chem. Lett.13(4),613–616 (2003).
  Medline CASGoogle Scholar
• 109  Niiro H, Azuma H, Tanago S et al. (3Z)-2-acetylamino-3-octadecen-1-ol as a potent apoptotic agent against HL-60 cells. Bioorg. Med. Chem.12(1),45–51 (2004).
  Medline CASGoogle Scholar
• 110  Bedia C, Canals D, Matabosch X et al. Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem. Phys. Lipids156(1–2),33–40 (2008).
  Medline CASGoogle Scholar
• 111  Lu X, Arthur G, Bittman R. Synthesis of a novel ceramide analogue via Tebbe methylenation and evaluation of its antiproliferative activity. Org. Lett.7(8),1645–1648 (2005).
  Medline CASGoogle Scholar
• 112  Kang JH, Garg H, Sigano DM, Francella N, Blumenthal R, Marquez VE. Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency. Bioorg. Med. Chem.17(4),1498–1505 (2009).
  Medline CASGoogle Scholar
• 113  Singh A, Ha HJ, Park J, Kim JH, Lee WK. 3,4-disubstituted oxazolidin-2-ones as constrained ceramide analogs with anticancer activities. Bioorg. Med. Chem.19(21),6174–6181 (2011).
  Medline CASGoogle Scholar
• 114  Yasuda S, Kitagawa H, Ueno M et al. A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis. J. Biol. Chem.276(47),43994–44002 (2001).
  Medline CASGoogle Scholar
• 115  Duriš A, Wiesenganger T, Moravcíková D et al. Expedient and practical synthesis of CERT-dependent ceramide trafficking inhibitor HPA-12 and its analogues. Org. Lett.13(7),1642–1645 (2011).
  Medline CASGoogle Scholar
• 116  Nakamura Y, Matsubara R, Kitagawa H et al. Stereoselective synthesis and structure-activity relationship of novel ceramide trafficking inhibitors. (1R,3R)-N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecanamide and its analogues. J. Med. Chem.46(17),3688–3695 (2003).
  Medline CASGoogle Scholar
• 117  Camacho L, Simbari F, Garrido M et al. 3-deoxy-3,4-dehydro analogs of XM462. Preparation and activity on sphingolipid metabolism and cell fate. Bioorg. Med. Chem.20(10),3173–3179 (2012).
  Medline CASGoogle Scholar
• 118  Novgorodov SA, Szulc ZM, Luberto C et al. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem.280(16),16096–16105 (2005).
  Medline CASGoogle Scholar
• 119  Kim S, Cho M, Lee T, Lee S, Min HY, Lee SK. Design, synthesis, and preliminary biological evaluation of a novel triazole analogue of ceramide. Bioorg. Med. Chem. Lett.17(16),4584–4587 (2007).
  Medline CASGoogle Scholar
• 120  Grijalvo S, Bedia C, Triola G et al. Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues. Chem. Phys. Lipids144(1),69–84 (2006).
  Medline CASGoogle Scholar
• 121  Senkal CE, Ponnusamy S, Rossi MJ et al. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.?. J. Pharmacol. Exp. Ther.317(3),1188–1199 (2006).
  Medline CASGoogle Scholar
• 122  Separovic D, Saad ZH, Edwin EA et al. C16-ceramide analog combined with Pc 4 photodynamic therapy evokes enhanced total ceramide accumulation, promotion of DEVDase activation in the absence of apoptosis, and augmented overall cell killing. J. Lipids doi:10.1155/2011/713867 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 123  Dindo D, Dahm F, Szulc Z et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol. Cancer Ther.5(6),1520–1529 (2006).
  Medline CASGoogle Scholar
• 124  Johnson CR, Chun J, Bittman R, Jarvis WD. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells. J. Pharmacol. Exp. Ther.309(2),452–461 (2004).
  Medline CASGoogle Scholar
• 125  Antoon JW, Liu J, Ponnapakkam AP, Gestaut MM, Foroozesh M, Beckman BS. Novel D: -erythroN-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother. Pharmacol.65(6),1191–1195 (2010).
  Medline CASGoogle Scholar
• 126  Kim JW, Kim YW, Inagaki Y et al. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg. Med. Chem.13(10),3475–3485 (2005).
  Medline CASGoogle Scholar
• 127  Oh JE, So KS, Lim SJ, Kim MY. Induction of apoptotic cell death by a ceramide analog in PC-3 prostate cancer cells. Arch. Pharm. Res.29(12),1140–1146 (2006).
  Medline CASGoogle Scholar
• 128  Wong L, Tan SS, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J. Med. Chem.52(12),3618–3626 (2009).
  Medline CASGoogle Scholar
• 129  Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J. Med. Chem.52(18),5748–5752 (2009).
  Medline CASGoogle Scholar
• 130  Liu J, Antoon JW, Ponnapakkam A, Beckman BS, Foroozesh M. Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorg. Med. Chem.18(14),5316–5322 (2010).
  Medline CASGoogle Scholar
• 131  Antoon JW, Beckman BS. Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. Bioorg. Med. Chem. Lett.22(7),2624–2628 (2012).
  Medline CASGoogle Scholar
• 132  Nichols CE, Lamb HK, Lockyer M et al. Characterization of Salmonella typhimurium YegS, a putative lipid kinase homologous to eukaryotic sphingosine and diacylglycerol kinases. Proteins68(1),13–25 (2007).
  Medline CASGoogle Scholar
• 133  Cho US, Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature445(7123),53–57 (2007).
  Medline CASGoogle Scholar
• 134  Inoue T, Okino N, Kakuta Y et al. Mechanistic insights into the hydrolysis and synthesis of ceramide by neutral ceramidase. J. Biol. Chem.284(14),9566–9577 (2009).
  Medline CASGoogle Scholar